Renal Cell Carcinoma
Conditions
Interventions
Test group:Intravenous injection of tislelizumab, concurrently with stereotactic body radiation therapy (SBRT) for a consecutive 12-week treatment course.
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age >= 18 years; (2) TNM staging T3-4N0-1M0-1; (3) Eastern Cooperative Oncology Group (ECOG) performance status <= 1; (4) Life expectancy of at least 3 months; (5) Adequate bone marrow, renal, and hepatic function, and normal blood test results.
Exclusion criteria
Exclusion criteria: (1) Previous use of other antineoplastic agents; (2) Recent history of cardiac or vascular events or other conditions that preclude surgical treatment; (3) Participation in other clinical trials within the past 3 months; (4) Lack of legal capacity or limited legal capacity; (5) Contraindications, allergies, or adverse reactions to radiotherapy and tislelizumab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS;Overall Survival, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR;Local Control Rate, LCR;the presence or absence of tumor metastasis and recurrence;Adverse reaction, AR; | — |
Countries
China
Contacts
Public ContactBaihetiya·Azhati
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed